Graybug Vision Inc. (GRAY)

[TruckingAngler]

GRAY 4/27/2022: Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting May 1-4, 2022.

" Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a poster presentation of preclinical data for GB-401 in primary open-angle glaucoma (POAG) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held at the Colorado Convention Center in Denver from May 1-4, 2022.

Information is listed below and available on the ARVO website.
In Vitro and In Vivo Characterizations of GB-401, a Sustained-Release Intravitreal Implant Containing a Beta-Adrenergic Antagonist Prodrug for POAG
Presenter: Yun Yu, PhD, Associate Director R&D, Graybug Vision
Poster Session: Drug Delivery
Date and Time: Wednesday May 4, 2022; 12:30 – 2:30 PM MT (2:30 – 4:30 PM ET). Location: Poster Hall - F0151 "

GLTA
..
..